Product Description
Amorolfine 5% and ciclopirox 8% nail lacquers are commonly used in topical treatment of onychomycosis. (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4360009/)
Mechanisms of Action: D14 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Topical
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Chile | China | Colombia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Ireland | Israel | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | New Zealand | Norway | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | Uruguay | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: Galderma
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Onychomycosis|Foot Dermatoses
Phase 2: Onychomycosis|Nail Diseases|Skin Diseases, Infectious
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ChiCTR2300074178 | N/A |
Not yet recruiting |
Onychomycosis |
2024-10-31 |
|
| ChiCTR-INR-17013504 | N/A |
Not yet recruiting |
Onychomycosis |
2019-12-31 |
|
| 391/2558(EC1) | P4 |
Completed |
Onychomycosis |
2019-06-01 |
|
| CU_MBPDT_for_Onychomycosis | N/A |
Unknown status |
Onychomycosis |
2018-12-30 |